It’s not every day that lab leaders overwhelmingly agree—but in a recent survey, 86% said precision medicine has moved beyond the hype, with AI-driven #pathology playing a pivotal role in that evolution. Our CSO Nathan Buchbinder breaks down what this shift means for the future

Happy National Intern Day to the future of tech.

Deep LIS integration is the long-term goal of a #digitalpathology transformation. This is why we've prioritized interoperability from day one—recently announcing the integration of Concentriq w/ 100+ LIS instances, including CoPath, Epic Beaker, NovoPath, LigoLab, + Orchard

Check-in: The Pathologist revisited January’s #digitalpathology + AI predictions (spoiler: they’re showing up in the wild). We loved seeing plenty of familiar voices in the mix from our own Nathan Buchbinder, customers, partners, + industry friends. thepathologist.com/issues/2025/ar…

Dennis is an amazing storyteller for the pathology community

Biopharma teams aren’t debating whether to invest in digital pathology + AI; they’re scaling with intent to: – Move trials faster – Improve read quality – Turn proprietary data into a compounding advantage Learn more in a webinar hosted by Drug Discovery World w/ our CSO

We asked AI to observe the pathologist in it's natural habitat. How did it do?

Trial samples shouldn’t earn more air miles than investigators. In Drug Discovery & Development, Brian Buntz captures the paradox: pathologists can sign out cases from anywhere, yet clinical-trial tissues still travel around the world on glass slides. Read more from him and our friends at

Michael’s summer with us was full of big ideas, collaborative wins, + moments that reminded us why fresh perspectives matter. Villanova University gets him back now, but we’re grateful for his contributions + excited to see what he does next.

From first study to first approval, your science deserves a platform that grows with you. Concentriq LS, now packaged for biotechs + small and mid-sized CROs on the way up. proscia.com/emerging-biote…